At UHN, we strive to deliver Compassionate Care & Caring. Learn more about the services and supports that are available to you throughout your journey.
Our UHN programs and services are among the most advanced in the world. We have grouped our physicians,
staff, services and resources into 10 medical programs to meet the needs of our patients and help us make
the most of our resources.
At the heart of everything we do at UHN are our Healthcare Professionals. Refer a patient to one of our 12 medical programs. Learn more about the resources and opportunities available for professional growth.
University Health Network has grown to be one of the largest research and teaching hospital networks in Canada - pioneers in improving the lives of patients. Our long history of health professions education at Toronto General, Toronto Western, Princess Margaret and Toronto Rehab hospitals has consistently advanced the science of education.
University Health Network is a health care and medical research organization in
Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international
source for discovery, education and patient care.
Being touched by illness affects us in different ways. Many people want to give back to the community
and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one
of our experts for an interview. It's also the place to find UHN media policies and catch up on our news stories, videos, media releases,
podcasts and more.
Toronto (Aug. 15, 2016) – Prostate cancer researchers studying genetic variations have pinpointed 45 genes associated with disease development and progression.
Principal investigator Hansen He says the findings published online today in Nature Genetics show how these genes – known as "noncoding RNA" – function in activating the disease process. Dr. He, an epigeneticist, is a Scientist at the Princess Margaret Cancer Centre, University Health Network. He is also Assistant Professor in the Department of Medical Biophysics, University of Toronto.
"Our research looked at genetic variations associated with prostate cancer and found that about half of these variations may function through noncoding genes rather than the protein-coding genes. In other words, we have discovered that noncoding RNA has a very important function in driving prostate cancer development and disease progression."
Dr. He says: "In prostate cancer there are more than 100 known risk regions associated with the development and progression of the disease, but for most of them we don't know how. In our work, we found that half those risk regions may function through noncoding genes."
Dr. He says that integrating this new knowledge about genetic variations and the function of noncoding RNA moves the science closer to developing a clinical biomarker to advance personalized cancer medicine for patients by being able to predict who will develop prostate cancer and whether or not it will be aggressive.
The research team collaborated with the Princess Margaret Genome Centre and delved further into the genetic variations associated with noncoding RNA PCAT1, which is already known to be highly expressed in prostate cancer patients, to zero in on how the noncoding genes function.
"Noncoding RNA has many functions and in this study we found that PCAT1 functions as a kind of glue to attract different protein complexes together, and guide them to specific genomic location to activate their target gene expression that starts the disease process."
"We are going to expand this knowledge as we research the other 44 genes associated with genetic variations," says Dr. He.
"Cancer is very smart to take every possible way to survive and use every piece of our genome. If research only focuses on the two percent of the genome that is the protein- coding genes, we will have limited understanding of how the cancer can survive. We cannot achieve personalized cancer medicine without understanding the other 98 per cent of our genome."
The other 98 percent – what used to be called 'junk DNA' because it was outside the protein-coding genes with no known function – is now providing a treasure trove to epigeneticists such as Dr. He.
"The major contribution of our work is to the link genetic variations outside of the gene to noncoding genes rather than protein-coding genes, which have been the traditional research focus."
The research was funded by The Princess Margaret Cancer Foundation, Prostate Cancer Canada, the Canadian Institutes of Health Research, the Natural Sciences and Engineering Research Council of Canada, the Canada Foundation for Innovation, the Ontario Research Fund, the Ontario Institute for Cancer Research, the Women in Insurance Cancer Crusade and the Canadian Cancer Society.
The Princess Margaret Cancer Centre has achieved an international reputation as a global leader in the fight against cancer and delivering personalized cancer medicine. The Princess Margaret, one of the top five international cancer research centres, is a member of the University Health Network, which also includes Toronto General Hospital, Toronto Western Hospital, Toronto Rehabilitation Institute and the Michener Institute for Education; all affiliated with the University of Toronto. For more information, go to
Phone: 416 340 4636